neuroCare´s mission is to empower clinicians with an evidence-based approach to integrate neuromodulation techniques into clinical practice. neuroCare personalises treatment following a detailed assessment and hence is able to achieve optimal individual outcomes employing scientifically proven protocols. For example, neuroCare’s assessment analyses sleep and circadian rhythm as much as psycho-diagnostic, genetic and other biomarkers in a truly holistic manner. This approach empowers clinicians to provide personalised and medication-free therapy that truly addresses the root causes by rewiring the patient’s brain with positive emotional and behavioural patterns for the long term.
neuroCare is vertically integrated, operating its own Clinics as well as providing its technologies, Standard Operating Procedures, services and education to its inhouse and third party clinics through its Solutions division. Within the Solutions division, neuroCademy provides Training & Supervision and neuroConn provides neuromodulation technology. These key building blocks enable neuroCare to support a growing network of clinicians.
The origin of neuroCare’s Solutions division lies in neuroConn, based in Thüringen, Germany. At this location, the company conducts its R&D in close coöperation with the University of Ilmenau and manufactures its core software and devices.
neuroCare is focused on rolling out its strong business model globally by significantly increasing its network of inhouse and third party clinics. The company currently has 16 clinics and is primed for rapid growth in the years to come. Longer term the company is targeting an IPO to fund its global expansion, and now the company has signed an investment agreement with bm|t (beteiligungsmanagement Thüringen), an institutional investor. According to this agreement, bm|t will become an anchor investor and help fund the next stage of the company´s growth by investing up to 50% of the required capital.
Given neuroCare´s strong presence in Thüringen, it was a natural fit to add bm|t as an investor. bm|t is the premier investor in the state of Thüringen and has a wealth of life science investing experience, including investments in multiple publicly-traded healthcare companies.
Kevin Reeder, bm|t´s CEO, said of the company´s investment in neuroCare, “We could not be more pleased to have invested in neuroCare. We believe strongly in the company´s leadership and vision and see a straight-line path for the company to become a global leader as a provider of high-quality mental health and performance solutions.”
Tom Mechtersheimer, neuroCare´s founder and Executive Chair, concluded by stating that “neuroCare is driving the future of managing mental health and cognitive performance with personalised, optimal and measurable outcomes for every patient or client.”
About neuroCare Group
The neuroCare Group (nCG) is a fast-growing, vertically-integrated company providing a holistic and personalised approach for improving mental health and performance. By integrating neuromodulation technology with best process and working in synergy with the clinicians, neuroCare is achieving best-in-class clinical outcome for patients. nCG is employing 130 people serving around 1500 patients per annum in currently 16 clinics in Australia, the Netherlands and the USA, whilst its technology solutions backbone is in Germany.
Erfurt-based, beteiligungsmanagement Thüringen (bm|t) – a subsidiary of the Thüringen Development Bank, is the first address for investments in Thüringen, Germany. bm|t currently manages eight investment funds with a total volume of 320M EUR. bm|t invests in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.